The authors find surprising that these activities have not yet been fully valued and supported by NHS: for example, the IHC characterization with ER, PgR, HER2 and Ki-67 antibodies of BC patients is still not reimbursed in Italy21, an approach impinging proper staffing and the use of validated reagent kits in favor of less expensive lab developed tests. Here, ERBB2 is linked to breast cancer.